ClinicalTrials.gg
CompletedNCT00002370Updated Jun 24, 2005

Study of Itraconazole in Patients With Advanced HIV Infection

An interventional study of Itraconazole in HIV Infections, sponsored by Janssen, LP. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Janssen, LP (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in HIV Infections by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. HIV Infections · Johnson & Johnson.

Enrollment
23rd of 39
36 · median 49
No phase
7 of 46
none open now
Registered
1st of 46
by date

Among the 46 studies in HIV Infections by Johnson & Johnson, this one is the 23rd largest by enrollment of the 39 interventional ones that give a count, is one of 7 with no phase, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 46 studies in HIV Infections by Johnson & Johnson is open now. The open studies under HIV Infections, anywhere →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 46 studies in HIV Infections by Johnson & Johnson as a file.
02

Study summary

To demonstrate a dosage regimen for intravenous itraconazole that produces a plasma concentration range comparable to that obtained after currently used oral dosages of itraconazole oral solution; and to obtain preliminary safety data in patients with advanced HIV disease.

Read the detailed description

Patients will receive intravenous itraconazole solution twice daily for 2 days and then once daily for five additional days. Patients then randomized to receive twice-daily or once-daily itraconazole oral solution for an additional 28 days.

03

Conditions studied

  • HIV Infections

Keywords

  • Itraconazole
  • Administration, Oral
  • Antifungal Agents
  • Acquired Immunodeficiency Syndrome
  • Drug Administration Schedule
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Concurrent Medication:

Allowed:

Antiretroviral therapy providing patient has already been on a stable, unchanged regimen for 8 weeks prior to study entry.

Patients must have:

  • Documented infection.
  • \< 300 cells/mm3.
  • No abnormalities, elicited by history and physical examination.
  • No clinically significant abnormalities in blood count, biochemical profile, or urinalysis within 2 weeks of study entry.
  • Negative urine screening.
  • No clinically significant abnormalities of .

Prior Medication:

Allowed:

Antiretroviral therapy providing patient has been on a stable, unchanged regimen for 8 weeks prior to study entry.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

  • Acute opportunistic infection or other significant concurrent illness that would preclude participation for the required 36 days.
  • Unable to swallow oral solution.
  • Obesity greater than 25% of ideal body weight.

Concurrent Medication:

Excluded:

  • Rifampin.
  • Rifabutin.
  • Phenobarbital.
  • Phenytoin.
  • Carbamazepine.
  • Digoxin.
  • Warfarin.
  • Midazolam.
  • Triazolam.
  • Terfenadine.
  • Astemizole.
  • Cisapride.
  • H2 blockers.
  • Omeprazole.
  • Continual antacids.
  • Didanosine.
  • Any medication known to affect absorption, metabolism or excretion of imidazole or azole compounds.

Patients with the following prior symptoms and conditions are excluded:

  • Previous to azole antifungals.
  • History of surgical procedure that may interfere with absorption of itraconazole.
  • History of significant blood loss in the previous 30 days.

Prior Medication:

Excluded:

Excluded within 15 days prior to study entry:

  • Rifampin.
  • Rifabutin.
  • Phenobarbital.
  • Phenytoin.
  • Carbamazepine.
  • Digoxin.
  • Warfarin.
  • Midazolam.
  • Triazolam.

Excluded within 8 weeks prior to study entry:

  • Change in antiretroviral therapy.

Risk Behavior:

Excluded:

Patients who chew tobacco or regularly smoke more than 10 cigarettes per day.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Enrollment
36 participants

Interventions

06

Study locations

1 site
  • Erie County Med Ctr / Pharmacy D
    Buffalo, New York 14215, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002370
Lead sponsor
Janssen, LP
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 1997. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion